Skip to main content

Advertisement

SpringerLink
Log in

The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The P53–MDM2 pathway plays a central role in sarcoma pathogenesis. Functional P53 Arg72Pro and MDM2 T309G single-nucleotide polymorphisms (SNP) are considered to have significant effects on risk of sarcomas.

Methods

Several molecular epidemiology studies have evaluated how these genetic variants are involved in sarcoma development, but the conclusions are inconsistent. Therefore, we conducted this meta-analysis to systematically examine the association between these functional SNPs and sarcoma risk.

Results

There are four studies eligible for P53 Arg72Pro SNP (466 sarcoma patients and 552 controls), and three studies for MDM2 T309G SNP (355 sarcoma patients and 645 controls). Pooled odds ratios were appropriately calculated using either fixed-effect model or random-effect model. We did not find a significant association between P53 Arg72Pro polymorphism and sarcoma risk. However, in a stratified analysis, a statistically significant correlation between this SNP and osteosarcoma risk was observed. For MDM2 T309G variant, pooled results from the meta-analysis indicate that carriers of TG and GG genotypes showed a 34% increased risk to develop sarcomas compared to TT carriers.

Conclusion

These results suggest that the functional MDM2 T309G genetic variant may play a more important role in carcinogenesis of sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin JP, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694–698

    Article  PubMed  CAS  Google Scholar 

  • Almeida PS, Manoel WJ, Reis AA, Silva ER, Martins E, Paiva MV, Fraga AC Jr, Saddi VA (2008) TP53 codon 72 polymorphism in adult soft tissue sarcomas. Genet Mol Res 7:1344–1352

    Article  PubMed  CAS  Google Scholar 

  • Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J (2005) A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280:26776–26787

    Article  PubMed  CAS  Google Scholar 

  • Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12:461–468

    PubMed  CAS  Google Scholar 

  • Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133–1141

    Article  PubMed  CAS  Google Scholar 

  • Bhagwat GP, Naik KG, Sachdeva R, Bhushan V (1980) Disseminated lymphadenopathic Kaposi’s sarcoma in Zambian children. Med J Zambia 14:61–63

    PubMed  CAS  Google Scholar 

  • Bond GL, Levine AJ (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26:1317–1323

    Article  PubMed  CAS  Google Scholar 

  • Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602

    Article  PubMed  CAS  Google Scholar 

  • Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65:5481–5484

    Article  PubMed  CAS  Google Scholar 

  • Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, Biryamwaho B, Sempala SD, Giraldo G (1996) Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi’s sarcoma (KS) biopsies. Int J Cancer 65:25–28

    Article  PubMed  CAS  Google Scholar 

  • Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266:1865–1869

    Article  PubMed  CAS  Google Scholar 

  • Chen J, Wu X, Lin J, Levine AJ (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445–2452

    PubMed  CAS  Google Scholar 

  • Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8:25–37

    Article  PubMed  CAS  Google Scholar 

  • Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701–711

    Article  PubMed  CAS  Google Scholar 

  • Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365

    Article  PubMed  CAS  Google Scholar 

  • Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  • Eymin B, Gazzeri S, Brambilla C, Brambilla E (2002) Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 21:2750–2761

    Article  PubMed  CAS  Google Scholar 

  • Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O (1994) MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 86:1297–1302

    Article  PubMed  Google Scholar 

  • Friborg J Jr, Kong W, Hottiger MO, Nabel GJ (1999) p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402:889–894

    PubMed  CAS  Google Scholar 

  • Gallo RC (1998) The enigmas of Kaposi’s sarcoma. Science 282:1837–1839

    Article  PubMed  CAS  Google Scholar 

  • Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299

    Article  PubMed  CAS  Google Scholar 

  • Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65:9582–9587

    Article  PubMed  CAS  Google Scholar 

  • HuGE Literature Finder (2011). http://hugenavigator.net/HuGENavigator/startPagePubLit.do

  • Ito M, Barys L, O’Reilly T, Young S, Gorbatcheva B, Monahan J, Zumstein-Mecker S, Choong PF, Dickinson I, Crowe P, Hemmings C, Desai J, Thomas DM, Lisztwan J (2011) Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 17:416–426

    Article  PubMed  CAS  Google Scholar 

  • Kotilingam D, Lev DC, Lazar AJ, Pollock RE (2006) Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin 56:282–291 quiz 314–315

    Article  PubMed  Google Scholar 

  • Landers JE, Cassel SL, George DL (1997) Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57:3562–3568

    PubMed  CAS  Google Scholar 

  • Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231–2234

    PubMed  CAS  Google Scholar 

  • Lee HR, Toth Z, Shin YC, Lee JS, Chang H, Gu W, Oh TK, Kim MH, Jung JU (2009) Kaposi’s sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J Virol 83:6739–6747

    Article  PubMed  CAS  Google Scholar 

  • Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238

    Article  PubMed  CAS  Google Scholar 

  • Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    PubMed  CAS  Google Scholar 

  • Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9:714–723

    PubMed  CAS  Google Scholar 

  • Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543

    Article  PubMed  Google Scholar 

  • Oettle AG (1962) Geographical and racial differences in the frequency of Kaposi’s sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum 18:330–363

    PubMed  CAS  Google Scholar 

  • Ørsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG (2007) Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 204:1295–1301

    Article  PubMed  Google Scholar 

  • Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3–13

    Article  PubMed  Google Scholar 

  • Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P (2010) Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 22:64–69

    Article  PubMed  CAS  Google Scholar 

  • Petitti DB (1994) Of babies and bathwater. Am J Epidemiol 140:779–782

    PubMed  CAS  Google Scholar 

  • Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, Busam K, Cordon-Cardo C, Osman I (2001) HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61:7642–7646

    PubMed  CAS  Google Scholar 

  • Rayburn E, Zhang R, He J, Wang H (2005) MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5:27–41

    Article  PubMed  CAS  Google Scholar 

  • Savage SA, Burdett L, Troisi R, Douglass C, Hoover RN, Chanock SJ, National Osteosarcoma Etiology study group (2007) Germ-line genetic variation of TP53 in osteosarcoma. Pediatr Blood Cancer 49:28–33

    Article  PubMed  Google Scholar 

  • Si H, Robertson ES (2006) Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol 80:697–709

    Article  PubMed  CAS  Google Scholar 

  • Siddique M, Sabapathy K (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25:3489–3500

    Article  PubMed  CAS  Google Scholar 

  • Siegel JH, Janis R, Alper JC, Schutte H, Robbins L, Blaufox MD (1969) Disseminated visceral Kaposi’s sarcoma. Appearance after human renal homograft operation. JAMA 207:1493–1496

    Article  PubMed  CAS  Google Scholar 

  • Slavin G, Cameron HM, Forbes C, Mitchell RM (1970) Kaposi’s sarcoma in East African children: a report of 51 cases. J Pathol 100:187–199

    Article  PubMed  CAS  Google Scholar 

  • Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M (2009) Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 15:3550–3556

    Article  PubMed  CAS  Google Scholar 

  • Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Katongole-Mbidde E, Buonaguro L, Buonaguro FM (2009) TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi’s sarcoma in African and Caucasian patients. Oncology 77:328–334

    Article  PubMed  CAS  Google Scholar 

  • Tornesello ML, Buonaguro L, Cristillo M, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Viviano E, Romano N, Katongole-Mbidde E, Buonaguro FM (2011) MDM2 and CDKN1A gene polymorphisms and risk of Kaposi’s sarcoma in African and Caucasian patients. Biomarkers 16:42–50

    Article  PubMed  CAS  Google Scholar 

  • US National Library of Medicine, National Institutes of Health (2011) PubMed home page. http://preview.ncbi.nlm.nih.gov/pubmed

  • Vesely K, Jurajda M, Nenutil R, Vesela M (2009) Expression of p53, cyclin D1 and EGFR correlates with histological grade of adult soft tissue sarcomas: a study on tissue microarrays. Neoplasma 56:239–244

    Article  PubMed  CAS  Google Scholar 

  • Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310

    Article  PubMed  CAS  Google Scholar 

  • Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL (1999) Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 18:783–788

    Article  PubMed  CAS  Google Scholar 

  • Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D (2007) Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28:1996–2001

    Article  PubMed  Google Scholar 

  • Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ (2008) A navigator for human genome epidemiology. Nat Genet 40:124–125

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Beijing Nova Program (no. 2010B013 to M. Yang) and the Fundamental Research Funds for the Central Universities (no. ZZ1234 to M. Yang).

Conflict of interest

The authors declare no competing financial interests.

Author information

Authors and Affiliations

  1. Department of Orthopedics, Division of Surgery, Chinese PLA General Hospital, Beijing, China

    Xu Cai

  2. College of Life Science and Technology, Beijing University of Chemical Technology, P. O. Box 53, Beijing, 100029, China

    Ming Yang

Authors
  1. Xu Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cai, X., Yang, M. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol 138, 555–561 (2012). https://doi.org/10.1007/s00432-011-1124-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-011-1124-8

Keywords

Search

Navigation